Table 2:

Unadjusted Cox proportional hazards model for influence of clinical factors on efficacy outcomes.

Factor		Overall Survival		Distant Failure		Local Failure		Biochemical Failure
		HR 95% CI	P value	HR 95% CI	P value	HR 95% CI	P value	HR 95% CI	P value
T stage	T1 vs. T2	1.41 (0.51–3.92)	0.51	0.58 (0.24–1.39)	0.22	0.61 (0.24–1.59)	0.31	0.85 (0.39–1.85)	0.69
PSA	Continuous	1.07 (0.93–1.23)	0.33	0.93 (0.83–1.05)	0.25	0.91 (0.80–1.03)	0.14	0.91 (0.81–1.01)	0.08
Gleason Score	2–6 vs. 7	2.20 (0.78–6.22)	0.14	0.53 (0.22–1.28)	0.16	0.4 (0.15–1.06)	0.07	0.57 (0.26–1.26)	0.16
Age	Continuous	1.09 (0.99–1.20)	0.06	0.95 (0.89–1.02)	0.19	0.96 (0.88–1.03)	0.25	0.98 (0.92–1.04)	0.43
V100	Continuous	0.98 (0.91–1.06)	0.59	1.04 (0.97–1.11)	0.26	1.00 (0.93–1.08)	0.89	1.03 (0.97–1.10)	0.35
Days from EBRT	Continuous	1.00 (0.99–1.02)	0.90	1.00 (0.99–1.02)	0.64	1.00 (0.99–1.02)	0.47	1.01 (0.99–1.02)	0.33
Dose EBRT (Gy)	Continuous	1.01 (0.92–1.10)	0.90	0.94 (0.85–1.04)	0.21	0.97 (0.88–1.06)	0.46	0.92 (0.84–1.00)	0.050

HR=hazard ratio; CI=confidence interval; PSA=prostate specific antigen; EBRT=external beam radiation therapy; V100%=percentage of target volume receiving prescription brachytherapy dose